CancerDrs

Prostate Cancer clinical trials in Oregon

28 actively recruiting prostate cancer trials at 14 sites across Oregon.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Oregon:
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Portland Medical Center — Portland, Oregon
  • Providence Saint Vincent Medical Center — Portland, Oregon
  • Kaiser Permanente Northwest — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
  • Providence Hood River Memorial Hospital — Hood River, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Oregon:
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
  • Legacy Mount Hood Medical Center — Gresham, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Oregon:
  • Legacy Mount Hood Medical Center — Gresham, Oregon
  • Legacy Good Samaritan Hospital and Medical Center — Portland, Oregon
  • Oregon Health and Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Oregon:
  • Providence Portland Medical Center — Portland, Oregon
  • Providence Saint Vincent Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Oregon:
  • Compass Oncology — Portland, Oregon
  • VA Portland Health Care System — Portland, Oregon
  • Oregon Urology Institute — Springfield, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Oregon:
  • Oregon Health and Science University ( Site 0028) — Portland, Oregon
  • VA Portland Health Care System ( Site 0058) — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT06520345
Sites in Oregon:
  • OHSU Knight Cancer Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Oregon:
  • Saint Alphonsus Medical Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Oregon:
  • Oregon Health & Science University (OHSU) — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Oregon:
  • Oregon Health and Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Oregon:
  • Providence Portland Medical Center — Portland, Oregon
  • Oregon Health & Science University (3485 S. Bond) — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…

Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Oregon:
  • VA Portland Health Care System, Portland, OR — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a m…

Sponsor: Phanes Therapeutics
NCT ID: NCT05652686
Sites in Oregon:
  • Providence Portland Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurat…

Sponsor: Sun Pharmaceutical Industries Limited
NCT ID: NCT05422911
Sites in Oregon:
  • VA Portland Health Care System — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant pr…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06457919
Sites in Oregon:
  • Oregon Health & Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…

Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Oregon:
  • Research Site — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Enzalutamide will be administered at dose of 160 mg orally every day. All patients will be required to have at least one …

Sponsor: Mark Garzotto, MD
NCT ID: NCT03753243
Sites in Oregon:
  • VA Portland Healthcare System — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Oregon:
  • Exelixis Clinical Site #51 — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Sponsor: SystImmune Inc.
NCT ID: NCT07080242
Sites in Oregon:
  • Providence Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →
Recruiting NIH

Precision-Based Genomics in Prostate Cancer

Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04706663
Sites in Oregon:
  • Oregon Health Sciences University — Portland, Oregon
View on ClinicalTrials.gov →

Showing 25 of 28 trials with sites in Oregon. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07